scholarly journals Levetiracetam as a sensitizer of concurrent chemoradiotherapy in newly diagnosed glioblastoma: An open‐label phase 2 study

2021 ◽  
Author(s):  
Kihwan Hwang ◽  
Junhyung Kim ◽  
Seok‐Gu Kang ◽  
Tae‐Young Jung ◽  
Jeong Hoon Kim ◽  
...  
Keyword(s):  
Concurrent Chemoradiotherapy ◽  
Phase 2 ◽  
Newly Diagnosed ◽  
Open Label ◽  
Phase 2 Study ◽  
Open Label Phase ◽  
Newly Diagnosed Glioblastoma

Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan

2019 ◽  
Vol 111 (1) ◽  
pp. 65-74 ◽  
Author(s):  
Kohmei Kubo ◽  
Mitsuo Hori ◽  
Kensuke Ohta ◽  
Hiroshi Handa ◽  
Kiyohiko Hatake ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Newly Diagnosed ◽  
Open Label ◽  
Phase 2 Study ◽  
Open Label Phase

Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study

2015 ◽  
Vol 2 (1) ◽  
pp. e37-e46 ◽  
Author(s):  
Franck E Nicolini ◽  
Gabriel Etienne ◽  
Viviane Dubruille ◽  
Lydia Roy ◽  
Françoise Huguet ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Chronic Phase ◽  
Phase 2 ◽  
Newly Diagnosed ◽  
Open Label ◽  
Phase 2 Study ◽  
Open Label Phase ◽  
Peginterferon Alfa

An Open-label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib, Cyclophosphamide, and Dexamethasone (ICd) in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM)

2017 ◽  
Vol 17 ◽  
pp. S333-S334 ◽  
Author(s):  
Meletios Dimopoulos ◽  
Sebastian Grosicki ◽  
Wiesław Jędrzejczak ◽  
Hareth Nahi ◽  
Astrid Gruber ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Newly Diagnosed ◽  
Open Label ◽  
Phase 2 Study ◽  
Open Label Phase

scholarly journals Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study)

2020 ◽  
Vol 52 (2) ◽  
pp. 505-515
Author(s):  
Kihwan Hwang ◽  
Tae Min Kim ◽  
Chul-Kee Park ◽  
Jong Hee Chang ◽  
Tae-Young Jung ◽  
...  
Keyword(s):  
Treatment Group ◽  
Control Group ◽  
Phase 2 ◽  
Newly Diagnosed ◽  
Open Label ◽  
Adjuvant Temozolomide ◽  
Anaplastic Gliomas ◽  
Phase 2 Study ◽  
Open Label Phase ◽  
To Receive

PurposeWe investigated the efficacy of temozolomide during and after radiotherapy in Korean adults with anaplastic gliomas without 1p/19q co-deletion.Materials and MethodsThis was a randomized, open-label, phase 2 study and notably the first multicenter trial for Korean grade III glioma patients. Eligible patients were aged 18 years or older and had newly diagnosed non-co-deleted anaplastic glioma with an Eastern Cooperative Oncology Group performance status of 0-2. Patients were randomized 1:1 to receive radiotherapy alone (60 Gy in 30 fractions of 2 Gy) (control group, n=44) or to receive radiotherapy with concurrent temozolomide (75 mg/m<sup>2</sup>/day) followed by adjuvant temozolomide (150-200 mg/m<sup>2</sup>/day for 5 days during six 28-day cycles) (treatment group, n=40). The primary end-point was 2-year progression-free survival (PFS). Seventy patients (83.3%) were available for the analysis of the isocitrate dehydrogenase 1 gene (<i>IDH1</i>) mutation status.ResultsThe two-year PFS was 42.2% in the treatment group and 37.2% in the control group. Overall survival (OS) did not reach to significant difference between the groups. In multivariable analysis, age was a significant risk factor for PFS (hazard ratio [HR], 2.08; 95% confidence interval [CI], 1.04 to 4.16). The <i>IDH1</i> mutation was the only significant prognostic factor for PFS (HR, 0.28; 95% CI, 0.13 to 0.59) and OS (HR, 0.19; 95% CI, 0.07 to 0.50). Adverse events over grade 3 were seen in 16 patients (40.0%) in the treatment group and were reversible.ConclusionConcurrent and adjuvant temozolomide in Korean adults with newly diagnosed non-co- deleted anaplastic gliomas showed improved 2-year PFS. The survival benefit of this regimen needs further analysis with long-term follow-up at least more than 10 years.

scholarly journals ACTR-50. EFFECT OF CONCURRENT AND ADJUVANT TEMOZOLOMIDE ON SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED GRADE III GLIOMAS WITHOUT 1p/19q CO-DELETION: A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY (INTERIM RESULTS FROM THE KNOG-1101 STUDY)

2018 ◽  
Vol 20 (suppl_6) ◽  
pp. vi23-vi23
Author(s):  
Chae-Yong Kim ◽  
Kihwan Hwang ◽  
Tae Min Kim ◽  
Chul-Kee Park ◽  
Jong Hee Chang ◽  
...  
Keyword(s):  
Phase 2 ◽  
Newly Diagnosed ◽  
Open Label ◽  
Adjuvant Temozolomide ◽  
Phase 2 Study ◽  
Open Label Phase ◽  
Grade Iii

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

2020 ◽  
Vol 21 (2) ◽  
pp. 207-221 ◽  
Author(s):  
Sagar Lonial ◽  
Hans C Lee ◽  
Ashraf Badros ◽  
Suzanne Trudel ◽  
Ajay K Nooka ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Open Label ◽  
Refractory Multiple Myeloma ◽  
Phase 2 Study ◽  
Open Label Phase

scholarly journals Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma

2016 ◽  
Vol 27 ◽  
pp. vi380 ◽  
Author(s):  
J. Chesney ◽  
F. Collichio ◽  
R.H.I. Andtbacka ◽  
I. Puzanov ◽  
J. Glaspy ◽  
...  
Keyword(s):  
Stage Iiib ◽  
Phase 2 ◽  
Talimogene Laherparepvec ◽  
Open Label ◽  
Safety And Efficacy ◽  
Phase 2 Study ◽  
Open Label Phase

scholarly journals Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study

2011 ◽  
Vol 17 (21) ◽  
pp. 6905-6913 ◽  
Author(s):  
Richard S. Finn ◽  
Carmelo Bengala ◽  
Nuhad Ibrahim ◽  
Henri Roché ◽  
Joseph Sparano ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Single Agent ◽  
Phase 2 ◽  
Open Label ◽  
Phase 2 Study ◽  
Open Label Phase

Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study

2015 ◽  
Vol 16 (4) ◽  
pp. 406-416 ◽  
Author(s):  
Akira Kawai ◽  
Nobuhito Araki ◽  
Hideshi Sugiura ◽  
Takafumi Ueda ◽  
Tsukasa Yonemoto ◽  
...  
Keyword(s):  
Supportive Care ◽  
Best Supportive Care ◽  
Phase 2 ◽  
Standard Chemotherapy ◽  
Open Label ◽  
Phase 2 Study ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document